Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Janney Montgomery Scott LLC cut its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 29.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 305,069 shares of the company's stock after selling 127,755 shares during the period. Janney Montgomery Scott LLC owned about 0.73% of Zevra Therapeutics worth $2,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC grew its stake in Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock valued at $48,000 after acquiring an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the first quarter valued at $64,000. Hunter Associates Investment Management LLC purchased a new position in Zevra Therapeutics during the third quarter valued at $92,000. SG Americas Securities LLC purchased a new position in Zevra Therapeutics during the third quarter valued at $105,000. Finally, City State Bank grew its stake in Zevra Therapeutics by 14.1% during the third quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZVRA has been the subject of several research analyst reports. Maxim Group raised their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Roth Mkm increased their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Monday, September 30th. Finally, Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Wednesday, September 18th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $20.83.

Zevra Therapeutics Trading Up 1.1 %

Shares of Zevra Therapeutics stock traded up $0.09 during trading on Wednesday, hitting $8.66. The stock had a trading volume of 1,373,542 shares, compared to its average volume of 542,776. The firm's fifty day simple moving average is $7.97 and its 200-day simple moving average is $6.44. The stock has a market cap of $455.69 million, a PE ratio of -4.40 and a beta of 1.93. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. Zevra Therapeutics, Inc. has a 12 month low of $4.11 and a 12 month high of $9.09.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. During the same quarter last year, the business posted ($0.15) EPS. As a group, sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.